РИТУКСИМАБ В ПЕДИАТРИЧЕСКОЙ РЕВМАТОЛОГИИ
Аннотация
В статье представлен обзор литературы, посвященный роли В лимфоцитов в патогенезе ревматических заболеваний и применению химерных анти-CD20 моноклональных антител (ритуксимаба) для лечения системной красной волчанки, системных васкулитов, ювенильного дерматомиозита, ювенильного артрита у детей. Результаты исследований свидетельствуют о хорошей переносимости, эффективности и безопасности ритуксимаба в детской ревматологической практике.
Ключевые слова: дети, В лимфоциты, ритуксимаб, лечение, деплеция.
(Вопросы современной педиатрии. – 2010;9(3):54-62)
Об авторах
Е.И. АлексееваРоссия
Р.В. Денисова
Россия
С.И. Валиева
Россия
Т.М. Бзарова
Россия
А.О. Лисицин
Россия
Список литературы
1. Noorchashm H., Noorchashm N., Kern J. et al. B–cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes. 1997; 46: 941–946.
2. Chan O.T., Hannum L.G., Haberman A.M. et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 1999; 189: 1639–1648.
3. Takemura S., Braun A., Crowson C. et al. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 2001; 167: 1072–1080.
4. O’Neill S.K., Shlomchik M.J., Glant T.T. et al. Antigenspecific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J. Immunol. 2005; 174: 3781–3788.
5. Wallace C.A., Sherry D.D. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J. Rheumatol. 1992; 19: 1604–1607.
6. Reiff A., Shaham B., Wood B.P. et al. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin. Exp. Rheumatol. 1995; 13: 113–118.
7. Balint G., Gergely P. Clinical immunotoxicity of antirheumatic drugs. Inflamm. Res. 1996; 45: 91–95.
8. Flato B., Vinje O., Forre O. Toxicity of antirheumatic and anti-inflammatory drugs in children. Clin. Rheumatol. 1998; 17: 505–510.
9. Anolik J.H., Barnard J., Cappione A. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004; 50: 3580–3590.
10. Brogan P.A., Dillon M.J. Vasculitis from the pediatric perspective. Curr. Rheumatol. Rep. 2000; 2: 411–416.
11. Dillon M.J. Vasculitis treatment – new therapeutic approaches. Eur. J. Pediatr. 2006; 165: 351–357.
12. Langford C.A. Small-vessel vasculitis: therapeutic management. Curr. Rheumatol. Rep. 2007; 9: 328–335.
13. Wright E., Dillon M.J., Tullus K. Childhood vasculitis and plasma exchange. Eur. J. Pediatr. 2007; 166: 145–151.
14. Brogan P.A., Dillon M.J. The use of immunosuppressive and cytotoxic drugs in non-malignant disease. Arch. Dis. Child. 2000; 83: 259–264.
15. Jayne D. How to induce remission in primary systemic vasculitis. Best Pract. Res. Clin. Rheumatol. 2005; 19: 293–305.
16. Jayne D. Novel therapeutic approaches in vasculitis treatment. Pediatr. Nephrol. 2004; 19: 50.
17. Pavone L., Grasselli C., Chierici E. et al. Outcome and prognostic factors during the course of primary small-vessel vasculitides. J. Rheumatol. 2006; 33: 1299–306.
18. Langford C.A., Talar-Williams C., Barron K.S. et al. Use of a cyclophosphamideinduction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse. Am. J. Med. 2003; 114: 463–469.
19. Haubitz M., Koch K.M., Brunkhorst R. Survival and vasculitis activity in patients with
20. end-stage renal disease due to Wegener’s granulomatosis. Nephrol. Dial. Transplant 1998; 13: 1713–1718.
21. Eleftheriou D., Melo M., Marks S. et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology. 2009; 48: 978–986.
22. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med. 2005; 257: 540–548.
23. Aries P.M., Hellmich B., Voswinkel J. et al. Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis. 2006; 6: 853–858.
24. Smith K.G., Jones R.B., Burns S.M. et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 2006; 54: 2970–2982.
25. Stasi R., Stipa E., Del P.G. et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2006; 45: 1432–1436.
26. Keogh K.A., Ytterberg S.R., Fervenza F.C. et al. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. 2006; 173: 180–187.
27. Keogh K.A., Wylam M.E., Stone J.H. et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum. 2005; 52: 262–268.
28. Omdal R., Wildhagen K., Hansen T. et al. Anti-CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response. Scand. J. Rheumatol. 2005; 34: 229–232.
29. Pachman L.M. Juvenile dermatomyositis: immunogenetics, pathophysiology, and disease expression. Rheum. Dis. Clin. North. Am. 2002; 28: 579–602.
30. Mendez E.P., Lipton R., Ramsey-Goldman R. et al. et al. for the NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003; 49: 300–305.
31. Huber A., Feldman B.M. Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr. Rheumatol. Rep. 2005; 7: 441–446.
32. Stringer E. Feldman B.M. Advances in the treatment of juvenile dermatomyositis. Curr. Opin. Rheumatol. 2006; 18: 503–506.
33. Targoff I.N. Myositis specific autoantibodies. Curr. Rheumatol. Rep. 2006; 8: 196–203.
34. Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005; 52: 601–607.
35. Chiappetta N., Steier J., Gruber B. Rituximab in the treatment of refractory dermatomyositis. J. Clin. Rheumatol. 2005; 11: 264–266.
36. Noss E.H., Hausner-Sypek D.L., Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis. J. Rheumatol. 2006; 33: 1021–1026.
37. Dinh H.V., McCormack C., Hall S. et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J. Am. Acad. Dermatol. 2007; 56: 148–153.
38. Cooper M. A., Willingham D. L., Brown D. E. Rituximab for the Treatment of Juvenile Dermatomyositis. Arthritis & Rheumatism. 2007; 56 (9): 3107–3111.
39. Schmugge M., Revel-Vilk S., Hiraki L. et al. Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. J. Pediatr. 2003; 143 (5): 666–669.
40. Arnal C., Piette J.C., Le´one J. et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J. Rheumatol. 2002; 29 (1): 75–83.
41. Ng K.P., Cambridge G., Leandro M.J. et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann. Rheum. Dis. 2007; 66 (9): 1259–1262.
42. Leandro M.J., Cambridge G., Edwards J.C. et al. B cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005; 44: 1542–1545.
43. Nobili B. Anti-CD20 monoclonal antibody (rituximab) for lifethreatening autoimmune hemolytic anemia in a patient with systemic lupus erythematosus. Br. J. Hematol. 2002; 116: 465–467.
44. Cate R., Smiers F.J., Bredius R.G. et al. Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus. Rheumatology (Oxford). 2004; 43: 244.
45. Edelbauer M., Jungraithmayr T., Zimmerhackl L.B. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr. Nephrol. 2005; 20: 811–813.
46. Marks S.D., Patey S., Brogan P.A. et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005; 52: 3168–3174.
47. Willems M., Haddad E., Niaudet P. et al. French Pediatric-Onset SLE Study Group. Rituximab therapy for childhood-onset systemic lupus Erythematosus. J. Pediatr. 2006; 148: 623–627.
48. Menon S., Hari P., Bagga A. Beneficial Effects of Rituximab Therapy for Systemic Lupus Erythematosus. Indian J Pediatrics. 2007; 74: 79–82
49. Jansson A. F., Wintergerst U., Renner E. D. et al. Rituximab-induced long-term remission in two children with SLE. Eur. J. Pediatr. 2007; 166: 177–181.
50. Tzaribachev N., Koetter I., Kuemmerle-Deschner J. Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases Journal. 2009; 2: 6609. Доступно на http://casesjournal.com/casesjournal/article/view/6609.
51. Abdwani R., Mani R. Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE. Lupus. 2009; 18: 460–464.
52. Salama A.D., Pusey C.D. Drug insight: rituxumab in renal disease and transplantation. Nature Clin. Prac. Nephrol. 2006; 2: 221-230.
53. Kunzmann V., Ruediger T., Hallek M. et al. Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti–CD20 monoclonal antibody (IDEC C2B8, rituximab) treatment. Blood. 2001; 98: 1991–1992.
54. Pescovitz M.D. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am. J. Transpl. 2006; 6: 859–866.
55. Kumar S., Benseler M., Kirby-Allen M. B-Cell Depletion for Autoimmune Thrombocytopenia and Autoimmune Hemolytic Anemia in Pediatric Systemic Lupus Erythematosus. Pediatrics. 2009; 123: 159–163.
56. Opastirakul S., Chartapisak W. Infection in children with lupus nephritis receiving pulse and oral cyclophosphamide therapy. Pediatr. Nephrol. 2005; 20: 1750–1755.
57. Nwobi O., Abitbol L., Chandar J. et al. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr. Nephrol. 2008; 23: 413–419.
58. Podolskaya A., Stadermann M., Pilkington C. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch. Dis. Child. 2008; 93: 401–406.
59. Smolen Keystone E.C., Emery P. et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66:143–150.
60. Foeldvari I., Bica B., Dedeoglu F. Efficacy of rituximab in RF factor negative juvenile idiopathic arthritis [FRI0450]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 502.
61. Алексеева Е.И., Валиева С.И., Бзарова Т.М. и др. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного артрита. Вопросы современной педиатрии. 2009; 8 (5): 19–30.
62. Wallace C.A., Ruperto N., Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 2004; 31 (11): 2290–2294.
63. Jansson A.F., Sengler C., Kümmerle-Deschner J. B-Cell depletion for autoinflammatory diseases in pediatric patients a retrospective study. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 300.
64. El–Hallak M., Bryce A. Binstadt, Alan M. Clinical Effects and Safety of Rituximab for Treatment of Refractory Pediatric Autoimmune Diseases. J. Pediatr. 2007; 150: 376–382.
65. Binstadt B., Caldas A., Stuart E. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J. Pediatr. 2003; 143: 598–604.
66. Polido-Pereira J., Ferreira D., Rodrigues A. et al. Rituximab Use in Pediatric Autoimmune Diseases. Contemporary Challenges in Autoimmunity. Ann. N.Y. Acad. Sci. 2009; 1173: 712–720.
Рецензия
Для цитирования:
Алексеева Е., Денисова Р., Валиева С., Бзарова Т., Лисицин А. РИТУКСИМАБ В ПЕДИАТРИЧЕСКОЙ РЕВМАТОЛОГИИ. Вопросы современной педиатрии. 2010;9(3):54-62.
For citation:
Alexeeva E., Denisova R., Valieva S., Bzarova T., Lisitsyn A. RITUXIMAB IN PEDIATRIC RHEUMATOLOGY. Current Pediatrics. 2010;9(3):54-62.
Послать статью по эл. почте 
